Navigation Links
InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
Date:5/4/2010

BRISBANE, Calif., May 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter for the New Drug Application (NDA) for Esbriet™ (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

A complete response letter is issued by the FDA's Center for Drug Evaluation and Research when the review of an application is completed, but there are one or more reasons that preclude the approval of the NDA at this time.  The FDA has requested an additional clinical trial to support the efficacy of Esbriet in IPF patients.  InterMune intends to meet with the FDA as soon as possible to explore the best ways to address the points raised by the Agency and to discuss pathways to approval.  

"After the positive FDA Advisory Committee meeting of March 9 at which the Committee recommended the approval of the pirfenidone NDA by a 9-3 margin, we are disappointed by this outcome," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune.  "We will meet with the FDA as soon as possible to understand their points of view and to determine the most appropriate path forward to expeditiously make Esbriet available to the approximately 100,000 patients with IPF and their families who suffer from this terrible disease and for whom no FDA-approved medicines exist."

Status of Esbriet (pirfenidone) in Europe

On March 2, 2010, InterMune announced that it h
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 29
2. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
3. InterMune Announces Proposed Public Offering of Common Stock
4. InterMune to Release Third Quarter Financial Results on November 5
5. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
8. InterMune to Release Second Quarter Financial Results on August 6
9. InterMune to Present at Goldman Sachs Healthcare Conference
10. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
11. InterMune to Release First Quarter Financial Results on April 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... led by Professor Andre Geim, a recipient of the 2010 ... a flow of electrons can magnetise graphene. ... potentially huge breakthrough in the field of spintronics. Spintronics ... spin of the electron, in addition to its fundamental electric ...
... IRVINE, Calif., April 15, 2011 CryoLife, Inc. (NYSE: ... and cardiovascular tissue processing company, today announced it has ... of Cardiogenesis Corporation ("Cardiogenesis") to acquire only 49.9 percent ... On April 14, 2011, Cardiogenesis, CryoLife and CryoLife,s wholly-owned ...
... Therapeutics, a company that manufactures novel blood plasma-based biomaterials ... on a Series A financing it will use to ... early clinical validation for the Company,s first products. ... Capital Partners, a private investment firm that invests in ...
Cached Biology Technology:New spin on graphene 2CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 2CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 3CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 4CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 5CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 6CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 7Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... & Science University researchers have identified some of the ... caused by multiple sclerosis (MS), complications of premature birth, ... clues about why the nervous system fails to repair ... of brain damage could be reversed. The research is ...
... information can be processed unconsciously when the area of ... temporarily shut down, according to research at Rice University ... Oct. 31 in the Proceedings of the National Academy ... has more than one pathway along which visual information ...
... identified some of the key factors that prevent the ... complications of premature birth, and other diseases and conditions. ... system fails to repair itself and suggest ways that ... reversed. The research is published in the August edition ...
Cached Biology News:Molecular Partners Required For Appropriate Neuronal Gene Repression 2Molecular Partners Required For Appropriate Neuronal Gene Repression 3Molecular Partners Required For Appropriate Neuronal Gene Repression 4Out of sight, out of mind? Not necessarily 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 3OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 4
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
... a synthetic peptide whose sequence is from the C-terminal end of the ... extends from amino acids 429 to 448 of RAR*. The sequence ... - V - S - P - S - S - V ... - Q - S - P - L - L - Q ...
... The ELx50 is a fast and versatile ... with our patented Dual-ActionTM 16-channel manifold. This ... the dispense and aspiration manifolds for overfill ... and 384-well formats. The problem of fitting ...
... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
Biology Products: